UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended ~~June~~December 3031, 2022

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from _________ to _________

Commission file number: 005-87668

PEAK PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada		26-1973257
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 85260

(Address of principal executive offices)

(480) 659-6404

(Registrant’s telephone number, including area code)

N/A

(Former address of principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of exchange on

which registered

None

Securities registered pursuant to section 12(g) of the Act:

Shares of common stock with a par value of $0.0001

(Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes o No x

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes o No x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o Accelerated filer o Non-accelerated ~~filer~~Filer x Smaller reporting company x Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes x No o

The number of shares outstanding of the registrant’s common stock as of ~~December~~February 168, ~~2022~~2023 was 78,363,567.

PEAK PHARMACEUTICALS, INC.

FORM 10-Q

FOR THE THREE ~~AND NINE~~ MONTHS ENDED ~~JUNE~~DECEMBER 3031, 2022 ~~and~~AND 2021

TABLE OF CONTENTS

		Page
PART I.	FINANCIAL INFORMATION
ITEM 1.	Financial Statements (Unaudited)	3
	Condensed Consolidated Balance Sheets as of June 30, 2022 and September 30, 2021	3
	Condensed Consolidated Balance Sheets as of December 31, 2022 and September 30, 2022	3
	Condensed Consolidated Statements of Operations for the Three and Nine Months Ended June 30, 2022 and 2021	4
	Condensed Consolidated Statements of Operations for the Three Months Ended December 31, 2022 and 2021	4
	Condensed Consolidated Statements of Stockholders' Deficit for the Three and Nine Months Ended June 30, 2022 and 2021	5
	Condensed Consolidated Statements of Stockholders’ Deficit for the Three Months Ended December 31, 2022 and 2021	5
	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended June 30, 2022 and 2021	6
	Condensed Consolidated Statements of Cash Flows for the Three Months Ended December 31, 2022 and 2021	6
	Notes to Condensed Consolidated Financial Statements	7
ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12
ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	16
ITEM 4.	Controls and Procedures	16
PART II.	OTHER INFORMATION
ITEM 1.	Legal Proceedings	18
ITEM 1A.	Risk Factors	18
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18
ITEM 3.	Defaults Upon Senior Securities	18
ITEM 4.	Mine Safety Disclosures	18
ITEM 5.	Other Information	18
ITEM 6.	Exhibits	19
SIGNATURES		20

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PEAK PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

CONDENSED CONSOLIDATED BALANCE SHEETS

	December 31,			September 30,
	2022			2022
Assets
Current assets:
Cash	$	96,720		$	127,599
Prepaid expenses		5,760			2,750
Total Assets	$	102,480		$	130,349

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities
Accounts payable (including $199,693 and $153,681 due to related parties)	$	307,146		$	224,548
Accrued liabilities		125,730			123,955
Convertible notes payable		10,000			10,000
Notes payable		228,000			228,000
Notes payable - related party		35,000			35,000
Total Liabilities		705,876			621,503

Stockholders’ deficit
Preferred stock, $0.0001 par value, 25,000,000 authorized, none issued or outstanding		-			-
Common stock, $0.0001 par value, 300,000,000 shares authorized, 78,363,567 shares issued and outstanding		7,836			7,836
Additional paid in capital		4,855,566			4,855,566
Accumulated deficit		(5,466,798	)		(5,354,556	)
Total Stockholders’ Deficit		(603,396	)		(491,154	)
Total Liabilities and Stockholders’ Deficit	$	102,480		$	130,349

(Unaudited)

	June 30,			September 30,
	2022			2021
Assets
Current assets:
Cash	$	131,340		$	261,152
Prepaid expenses		2,750			-
Total Assets	$	134,090		$	261,152
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities
Accounts payable (including $140,031 and $133,986 due to related parties)	$	175,095		$	214,136
Accrued liabilities		117,265			35,201
Convertible notes payable		10,000			20,000
Notes payable		228,000			283,000
Notes payable – related party		35,000			35,000
Total Liabilities		565,360			587,337
Stockholders’ deficit
Preferred stock, $0.0001 par value, 25,000,000 authorized, none issued or outstanding		-			-
Common stock, $0.0001 par value, 300,000,000 shares authorized, 78,363,567 shares issued and outstanding		7,836			7,836
Additional paid in capital		4,855,566			4,855,566
Accumulated deficit		(5,294,672	)		(5,189,587	)
Total Stockholders’ Deficit		(431,270	)		(326,185	)
Total Liabilities and Stockholders’ Deficit	$	134,090		$	261,152

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

PEAK PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For the Three Months Ended						~~For the Nine Months Ended~~
	June 30,						June 30,
	December 31,
	2022			2021			~~2022~~			~~2021~~
Operating expenses:
General and administrative (including fees paid to related party of $6,919 and $15,705, and $14,968 and $43,283, for the three and nine months ended March 31, 2022 and 2021, respectively)	$	12,091		$	16,845		$	110,715		$	65,060
General and administrative (including expenses to related party of $46,012 and $4,770)	$	110,412		$	52,063
Total operating expenses		12110,~~091~~412			1652,~~845~~063			~~110,715~~			~~65,060~~
Operating loss		(12110,~~091~~412	)		(1652,~~845~~063	)		~~(110,715~~	)		~~(65,060~~	)
Other expenses (income):
Other (expense) income:
Interest expense (including related party interest of $873 and $3, and $1,868 and $3, for the three and nine months ended March 31, 2022 and 2021, respectively)		7,951			2,361			24,784			7,241
Interest expense (including related party interest of $882 and $132)		(1,830	)		(8,831	)
Gain on forgiveness of debt		~~(28,875~~-	)		-1,539			~~(30,414~~	)		~~(3,029~~	)
Total other expenses (income), net		(20,924	)		2,361			(5,630	)		4,212
Total other expenses, net		(1,830	)		(7,292	)
Net income (loss)	$	8,833		$	(19,206	)	$	(105,085	)	$	(69,272	)
Net loss	$	(112,242	)	$	(59,355	)
Per share information:
Weighted average shares outstanding - basic		-			78,363,567			78,363,567			78,363,567
Weighted average shares outstanding - basic and diluted		78,363,567			78,363,567
Weighted average shares outstanding - diluted		82,003,049			-			-			-
Net loss per share - basic and diluted	$	(0.00	)	$	(0.00	)
Net loss per share - basic		-		$	0.00		$	(0.00	)	$	(0.00	)
Net income per share - diluted	$	(0.00	)		-			-			-

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

PEAK PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT FOR THE THREE ~~AND NINE~~ MONTHS ENDED ~~JUNE~~DECEMBER 3031, 2022 AND 2021 (Unaudited)

	Common Stock				Additional Paid		Accumulated
	Shares		Amount		In Capital		Deficit			Total
Balance, October 1, 2020		78,363,567	$	7,836	$	4,855,566	$	(5,113,498	)	$	(250,096	)
Net loss		-		-		-		(7,354	)		(7,354	)
Balance, December 31, 2020		78,363,567		7,836		4,855,566		(5,120,852	)		(257,450	)
Net loss		-		-		-		(42,712	)		(42,712	)
Balance, March 31, 2021		78,363,567		7,836		-		(5,163,564	)		(5,155,728	)
Net loss		-		-		-		(19,206	)		(19,206	)
Balance, June 30, 2021		78,363,567	$	7,836	$	4,855,566	$	(5,182,770	)	$	(319,368	)
Balance, October 1, 2021		78,363,567	$	7,836	$	4,855,566	$	(5,189,587	)	$	(326,185	)
Net loss		-		-		-		(59,355	)		(59,355	)
Balance, December 31, 2021		78,363,567	$	7,836	$	4,855,566	$	(5,248,942	)	$	(385,540	)
Net loss		-		-		-		(54,563	)		(54,563	)
Balance, October 1, 2022		78,363,567	$	7,836	$	4,855,566	$	(5,354,556	)	$	(491,154	)
Balance, March 31, 2022		78,363,567		7,836		4,855,566		(5,303,505	)		(440,103	)
Net loss		-		-		-		(112,242	)		(112,242	)
Net Income		-		-		-		8,833			8,833
Balance, December 31, 2022		78,363,567	$	7,836	$	4,855,566	$	(5,466,798	)	$	(603,396	)
Balance, June 30, 2022		78,363,567	$	7,836	$	4,855,566	$	(5,294,672	)	$	(431,270	)

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

PEAK PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE ~~NINE~~THREE MONTHS ENDED ~~JUNE~~DECEMBER 3031, 2022 AND 2021 (Unaudited)

	2022			2021
Cash flows from operating activities:
Net loss	$	(~~105~~112,~~085~~242	)	$	(6959,~~272~~355	)
Adjustment to reconcile net loss to net cash used in operating activities:
Gain on debt forgiveness		~~(30,414~~-	)		(31,~~029~~539	)
Change in operating assets and liabilities:
Prepaids		(2,750	)		-
Prepaid expenses		(3,010	)		(5,500	)
Accounts payable		~~(45~~36,~~086~~586	)		23(6,~~347~~216	)
Accounts payable - related parties		646,~~045~~012			41(9,~~761~~090	)
Accrued liabilities		821,~~064~~775			738,~~073~~102
Net cash used in operating activities		(6430,~~812~~879	)		(~~120~~43,598	)
Cash flows from financing activities:
Cash flows used in financing activities:
Proceeds from issuance of notes payable		-			37,500
Payments on notes payable		-			(20,000	)
Proceeds from issuance of note payable – related party		-			5,000
Payment on convertible note payable		-			(10,000	)
Payments on notes payable		(55,000	)		-
Net cash flows used in financing activities:		-			(30,000	)
Payment on convertible note payable		(10,000	)		-
Net change in cash		(30,879	)		(73,598	)
Net cash provided by financing activities		(65,000	)		42,500
Cash, beginning of period		127,599			261,152
Net change in cash		(129,812	)		42,380
Cash, end of period	$	96,720		$	187,554
Cash, beginning of period		261,152			408
Cash, end of period	$	131,340		$	42,788
Supplemental disclosure of cash flow information
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

PEAK PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1 – NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was incorporated in Nevada on December 18, 2007. After a number of name changes, we again, changed our name to Peak Pharmaceuticals, Inc. on December 23, 2014. This name was consistent with our business operations and plans relating to development, manufacturing and marketing of hemp-based nutraceutical and supplement products for the human and animal health markets. On October 1, 2015, we discontinued certain operations of the Company.

The Company is currently a “shell company” (as such term is defined in Rule 12b-2 under the Exchange Act).

Throughout this report, the terms “our,” “we,” “us,” and the “Company” refer to Peak Pharmaceuticals, Inc. and its wholly-owned subsidiary, Peak BioPharma Corp.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial statements, instructions to Form 10-Q, and Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in our annual report on Form 10-K for the year ended September 30, ~~2021~~2022. In management’s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation to make our financial statements not misleading have been included. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year, or any other period.

Basis of Consolidation

The unaudited condensed consolidated financial statements include the financial statements of the Company and our wholly owned subsidiary Peak BioPharma Corp. All inter-company balances and transactions among the companies have been eliminated upon consolidation.

Use of Estimates

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Significant estimates made in connection with the accompanying consolidated financial statements include the valuation allowances against net deferred tax assets and accounting for convertible debt.

Loss Per Share

We calculate net loss per share in accordance with ASC Topic 260, Earnings per Share. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period, and diluted earnings per share is computed by including common stock equivalents outstanding for the period in the denominator. For the three months ended ~~June~~December 3031, ~~2021 and for the nine months ended June 30,~~ 2022 and 2021, any equivalents would have been anti-dilutive as we had net losses for the periods then ~~ended.~~ ~~For the three months~~ ended ~~June 30, 2022, the common stock equivalents were dilutive as we had net income for the period then ended~~.

As of ~~September~~December 3031, 2021, the Company had two convertible notes with principal and accrued interest balances totaling and $32,366. During the nine months ended June 30, 2021, the Company repaid one of these notes and related accrued interest totaling $15,408. As of June 30, 2022, the Company had one convertible note ~~remaining~~ with principal and accrued interest totaling $1718,~~948~~067. The note holders are entitled, at their option, to convert all or a part of their ~~options~~principal and accrued interest at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01. These common stock equivalents of approximately ~~348~~163,~~482~~655 and ~~339~~271,~~159~~936 shares as of ~~June 30~~December 31, 2022 and 2021, respectively, are not included in the calculation of diluted EPS as their effect would be anti-dilutive.

As of ~~June~~December 3031, 2022 and September 30, ~~2021~~2022, the Company had 3,291,000 in stock options outstanding which are exercisable at the holders’ option, with an exercise price of $0.0067, which are not included in the calculation of diluted EPS as their effect would be anti-dilutive.

Recently Issued Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

From time to time, new accounting pronouncements are issued that we adopt as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective may have an impact on our results of operations and financial position.

On August 5, 2020, the FASB issued Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU’s amendments are effective for public business entities that are not smaller reporting companies for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The guidance may be early adopted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company has determined that the adoption of this guidance has no impact on its consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 amends the guidance on the impairment of financial instruments. This update adds an impairment model (known as the current expected credit losses model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes, as an allowance, its estimate of expected credit losses. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842). ASU 2019-10 changes the effective date of the credit loss standard (ASU 2016-13) to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years for smaller reporting companies. Further, the ASU clarifies that operating lease receivables are not within the scope of ASC 326-20 and should instead be accounted for under the new leasing standard, ASC 842. The Company has determined that the adoption of this guidance has no impact on its consolidated financial statements.

Recently Adopted Accounting Pronouncements

InThere ~~December~~were ~~2019,~~no ~~the~~recently ~~FASB~~adopted ~~issued ASU No. 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes (Topic 740), (“ASU 2019-12”), which simplifies income tax~~ accounting inpronouncements ~~various~~had ~~areas~~a ~~including,~~material ~~but~~effect ~~not~~on ~~limited to,~~ the accounting for hybrid tax regimes, tax implications related to business combinations, and interim period accounting for enacted changes in tax law, along with some codification improvements. ASU 2019-12 is effective for interim and annual periods beginning after December 15, 2020. The Company’s ~~adopted ASU 2019-12 on September 30, 2021 and has determined that the adoption of this guidance had no impact on its consolidated~~ financial statements.

In August 2018, the FASB issued ASU No. 2018-13, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The guidance is effective for all entities for fiscal years beginning after December 15, 2019, including interim periods therein. Early adoption is permitted for any eliminated or modified disclosures upon issuance of ASU 2018-13. The Company adopted ASU 2018-13 on October 1, 2020 and has determined that the adoption of this guidance had no impact on its consolidated financial statements.

NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS

As of ~~June~~December 3031, 2022, the Company had an accumulated deficit of $5,~~294~~466,~~672~~798 and a working capital deficiency of $~~431~~603,~~270~~396. During the ~~nine~~three months ended ~~June~~December 3031, 2022, the Company incurred a net loss of $~~105~~112,~~085~~242 and used cash in operating activities of $6430,~~812~~879. As of ~~June~~December 3031, 2022, the Company had cash of $~~131~~96,~~340~~720. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company recognizes it will need to raise additional capital in order to fund operations and meet its payment obligations. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company and whether the Company will generate revenues, become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds on favorable terms, it will have to develop and implement a plan to further extend payables and to raise capital through the issuance of debt or equity on less favorable terms until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.

Accordingly, the accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the unaudited condensed consolidated financial statements do not necessarily represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 3 – RELATED PARTY TRANSACTIONS

Parties, which can be corporations or individuals, are considered to be related if they have the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

Accounts payable – related parties are amounts payable to current and former officers and directors for services provided to the Company totaling $~~140~~199,~~031~~693 and $~~133~~153,~~986~~681, as of ~~June~~December 3031, 2022 and September 30, ~~2021~~2022, respectively. These amounts include accounts payable to an entity controlled by our sole officer and director for financial services such entity is incurring on behalf of the Company totaling $65124,~~154~~816 and $5978,~~109~~804 as of ~~June~~December 3031, 2022 and September 30, ~~2021~~2022, respectively. Total expense incurred related to this entity was ~~$6,919~~ ~~and~~ $1546,~~705,~~012 and $144,~~968~~770 ~~and $43,283,~~ for the three ~~and nine~~ months ended ~~June~~December 3031, 2022 and 2021, respectively, with no other related party expenses incurred. See Note 4 for certain related party debt.

NOTE 4 – CONVERTIBLE NOTES PAYABLE AND NOTES PAYABLE

Convertible Notes Payable

Loan with Trius Holdings Limited

On March 17, 2017, the Company entered into an agreement with Trius Holdings Limited (“Trius”). Pursuant to the terms of the agreement, Trius acquired a 12% convertible note with an aggregate face value of $10,000. The note matures in one year and is unsecured. Trius is entitled, at its option, to convert all or a part of the principal outstanding at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01. On May 11, 2018, the agreement had been amended to extend the maturing date of the note from March 21, 2018 to March 21, 2019. As of ~~June~~December 3031, 2022 and September 30, ~~2021~~2022, the total accrued interest owing under this note was $78,~~311~~ 067 and $67,~~205~~689, respectively. As of the date of this report, that date has not been extended, and the Company is accruing interest at the default interest rate of 15%.

Loan with Individual

On March 30, 2017, the Company entered into an agreement with an individual. Pursuant to the terms of the agreement, the individual acquired a 12% convertible note with an aggregate face value of $10,000. The note matures in one year and is unsecured. The individual is entitled, at its option, to convert all or a part of the principal outstanding at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01. The default interest rate is 15%. On May 11, 2018, the agreement had been amended to extend the maturing date of the note from March 30, 2018 to March 30, 2019. As of June 30, 2022 and September 30, 2021, the total accrued interest owing under this note was $0 and $6,160, respectively. On December 3, 2021, the Company repaid this loan and accrued interest in full.

Notes Payable

Loan with Mediapark Investments Limited

On January 10, 2018, the Company entered into an agreement with Mediapark Investments Limited (“Mediapark”.) Pursuant to the terms of the agreement, Mediapark acquired a 12% promissory note with an aggregate face value of $23,000. The note matures in 180 days on July 10, 2018 and is unsecured. As of July 9, 2018, the loan was extended to July 10, 2019. As of ~~June~~December 3031, 2022 and September 30, ~~2021~~ 2022, the total accrued interest owing under this note was $1416,~~412~~152 and $1115,~~813~~282, respectively. As of the date of this report, that ~~date~~ date has not been extended, and the Company is accruing interest at the default interest rate of 15%.

~~Loan~~Loans with ~~Individual~~Officer

On ~~April~~June 214, ~~2018~~2021, the Company entered into an agreement with anour ~~individual~~sole officer and director. Pursuant to the terms of the agreement, we received a promissory note in the amount of $205,000. The note is unsecured, is due and payable in full on ~~October~~December 231, ~~2018~~2021, and it accrues interest at a rate of 121.5% per annum. As of ~~the~~December ~~June 30~~31, 2022 and September 30, ~~2021~~2022, the total accrued interest owing under this note was $0 541 and $9415,~~883,~~ respectively. OnAs ~~December~~of 3,the ~~2021~~date of this report, the ~~Company~~due ~~repaid~~date ~~this~~has ~~loan~~not been extended and ~~accrued~~the Company is accruing interest inat ~~full~~the default interest rate of 10%.

~~Loan~~On September 28, 2021, the Company entered into a note payable with ~~Officer~~our sole officer and director for $30,000. The note is unsecured, is due and payable in full on December 31, 2021 and accrues interest at a rate of 1.5% per annum. As of the December 31, 2022 and September 30, 2022, the total accrued interest owing under this note was $3,116 and $2,360, respectively. As of the date of this report, that date has not been extended, and the Company is accruing interest at the default interest rate of 10%.

OnOther ~~June~~Notes 14, 2021, the Company entered into an agreement with our sole officer and director. Pursuant to the terms of the agreement, we received a promissory note in the amount of $5,000. The note is unsecured, is due and payable in full on December 31, 2021, and accrues interest at a rate of 1.5% per annum. As of June 30, 2022 and September 30, 2021, the total accrued interest owing under this note was $289 and $22, respectively. As of the date of this report, the due date has not been extended and the note is in default.Payable

During the ~~three~~twelve months ended September 30, 2021, the Company entered into atwelve ~~note~~notes payable ~~with~~totaling ~~our sole officer and director for~~ $30240,000. The ~~note~~notes isare unsecured, are is due and payable in full on ~~December~~September 3130, 2021, and ~~accrues~~accrue interest at a rate of 1.5% per annum. As of the ~~June~~ 30December 31, 2022 and September 30, ~~2021~~2022, the total accrued interest owing under ~~this~~these ~~note~~notes was $125,~~604~~911 and $223,250. ~~respectively~~In June 2022, the Company repaid one of the notes with a principal balance of $35,000. As of the date of this report, ~~that~~the ~~date~~due ~~has~~dates have not been extended, and the Company is accruing interest at the default interest rate of 10%.

Notes Payable Issued During the Twelve Months Ended September 30, 2021

During the twelve months ended September 30, 2021, the Company entered into twelve notes payable totaling $240,000. The notes are unsecured, are due and payable in full on September 30, 2021, and accrue interest at a rate of 1.5% per annum. As of the June 30, 2022 and September 30, 2021, the total accrued interest owing under these notes was $18,083 and $755. In June 2022, the Company repaid one of the notes with a principal balance of $35,000. As of the date of this report, that date has not been extended, and the Company is accruing interest at the default interest rate of 10%.

NOTE 5 – OPTIONS

No stock options were granted during the ~~nine~~three months ended ~~June~~December 3031, 2022 and 2021.

The following is a summary of outstanding stock options issued to employees and directors as of ~~June~~December 3031, 2022 and September 30, ~~2021~~2022:

	Number of Options		Exercise Price per Share		Average Remaining Term in Years
Outstanding June 30, 2022 and September 30, 2021		2,916,000	$	0.0067		1.70
Outstanding December 31, 2022 and September 30, 2022		2,916,000	$	0.0067		1.20
Exercisable, June 30, 2022 and September 30, 2021		2,916,000	$	0.0067		1.70
Exercisable, December 31, 2022 and September 30, 2022		2,916,000	$	0.0067		1.20

~~The following is a summary of outstanding stock options issued to non-employees, excluding directors, as of June 30, 2022 and September 30, 2021:~~10

The following is a summary of outstanding stock options issued to non-employees, excluding directors, as of December 31, 2022 and September 30, 2022:

	Number of Options		Exercise Price per Share		Average Remaining Term in Years
Outstanding June 30, 2022 and September 30, 2021		375,000	$	0.0067		1.29
Outstanding December 31, 2022 and September 30, 2022		375,000	$	0.0067		0.79
Exercisable, June 30, 2022 and September 30, 2021		375,000	$	0.0067		1.29
Exercisable, December 31, 2022 and September 30, 2022		375,000	$	0.0067		0.79

There was no equity-based compensation for the ~~nine~~three months ended ~~June~~December 3031, 2022 and 2021.

NOTE 6 – SUBSEQUENT EVENTS

On January 23, 2023, the Company executed a Settlement Agreement and Mutual Release with four parties for outstanding accounts payable, resulting in a gain on forgiveness of debt of approximately $45,490, including $24,340 from related parties.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

This report contains forward-looking statements. The following discussion should be read in conjunction with the financial statements and related notes contained in our Annual Report on Form 10-K, as filed with the Securities & Exchange Commission on December 19, 2022. Certain statements made in this discussion are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements are projections in respect of future events or financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology.

These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks in the section entitled “Risk Factors” set forth in our Annual Report on Form 10-K for the year ended September 30, ~~2021~~2022, as filed on December 19, 2022, any of which may cause our company’s or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These risks may cause the Company’s or its industry’s actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. The Company is under no duty to update any forward-looking statements after the date of this report to conform these statements to actual results.

As used in this quarterly report and unless otherwise indicated, the terms “we,” “us,” “our,” “Peak,” or the “Company” refer to Peak Pharmaceuticals, Inc, including our wholly-owned subsidiary Peak BioPharma Corp (“Peak BioPharma”). Unless otherwise specified, all dollar amounts are expressed in United States dollars.

Corporate History and Overview

We were first incorporated in Nevada as Surf A Movie Solutions, Inc. on December 18, 2007 to engage in the business of the development sale and marketing of online video sales. We were not successful in our efforts and discontinued this line of business. Since that time and until August 8, 2014, we were a “shell company” (as such term is defined in Rule 12b-2 under the Exchange Act).

On August 30, 2013, we changed our name to Frac Water Systems, Inc. and, on October 10, 2013, we decided to engage in the business of providing economically and environmentally sound solutions for the treatment and recycling of wastewater resulting principally from oil and gas exploration and production activities. Due to our research of the business opportunities, on December 31, 2013, we determined not to move forward with this line of business.

In early March 2014, we decided to enter into the business of developing, manufacturing and marketing pharmaceutical level products containing phytocannabinnoids, an abundant and pharmaceutically active component of industrial hemp, for the prevention and alleviation of various conditions and diseases. In connection therewith, on March 17, 2014, we changed our name to Cannabis Therapy Corporation and, on March 24, 2014, changed our trading symbol on OTC Markets to “CTCO”. On December 23, 2014, we changed our name to Peak Pharmaceuticals, Inc. and our trading symbol changed to “PKPH” on February 5, 2015.

In March 2014 we began operating as a bio-pharmaceutical and nutraceutical company seeking to develop, manufacture, market and sell safe, high quality, medicinal products based on extracts from hemp. Our primary initial focus was on exploitation of the exclusive license we received from Canna-Pet, LLC, a developer of ingestible health products for pets made from hemp. We had also taken initial steps related to development of over-the-counter, THC-free, hemp-based products for the human market for the prevention and alleviation of symptoms associated with inflammatory and auto-immune diseases.

On July 29, 2014, through our wholly-owned subsidiary, Peak BioPharma Corp., we entered into a License Agreement (the “License Agreement”) with Canna-Pet, LLC, (“Licensor”) a Washington limited liability corporation. They own the brand name “Canna-Pet” and certain related intellectual property including, but not limited to, trademarks and copyrights, formulations, recipes, production processes and systems, websites, domain names, customer lists, supplier lists, trade secrets and know-how, and other related intellectual property (collectively, the “Licensed Intellectual Property”). This is used by the Licensor in the conduct of its business related to the production and sale of medical products made from industrial hemp, which are intended exclusively for consumption by pets. Pursuant to the License Agreement, the Licensor granted to us a perpetual, exclusive, world-wide license to use the Licensed Intellectual Property in conjunction with our business and the production and sale of medical products made from industrial hemp, as well as the right to sublicense the Licensed Intellectual Property to third parties. The License Agreement gave us the right to produce and sell existing products utilizing the Licensed Intellectual Property and to develop new products, jointly with Licensor or otherwise, based upon the Licensed Intellectual Property. The License Agreement provided us with an immediate revenue source and access to Licensor’s customer base. The License Agreement specified that during the term of the license, all intellectual property rights in and to the Licensed Intellectual Property remain the exclusive property of Licensor.

In consideration of the grant of the license, we agreed to pay Licensor license fees in the form of royalty payments calculated based on gross proceeds received by us from sales of products manufactured, marketed or sold by us utilizing the Licensed Intellectual Property or any subsequently developed intellectual property which is jointly owned by us and Licensor. We began selling Canna-Pet products in October 2014.

Based upon recent regulatory activity related to imposition of restrictions and limitations on the sale of hemp-based health products for pets, we elected to terminate our license agreement with the Licensor, effective as of October 1, 2015, and to cease all operations relating to sale of hemp-based products for pets.

On October 12, 2015, we entered into an agreement for the termination (“Termination Agreement”) of the License Agreement, effectively selling the discontinued operations. Furthermore, based on advice from the Food and Drug Administration, as well as our regulatory counsel, we decided to revise our strategy and discontinue all efforts to develop and market hemp-based health products. We currently are pursuing to acquire or merge with an entity with significant operations in order to create a viable business model and value for our shareholders. Since October 2015 we have been a “shell company” (as such term is defined in Rule 12b-2 under the Exchange Act).

All of our business operations are carried out through our wholly owned subsidiary, Peak BioPharma Corp., a Colorado corporation. Throughout this Report, unless otherwise noted or required by the context, references to “the Company,” “us,” “we,” “our,” and similar terms refer to Peak Pharmaceuticals, Inc. and our wholly owned subsidiary, Peak BioPharma Corp.

We currently have authorized 325,000,000 shares of capital stock, consisting of (i) 300,000,000 shares of common stock, and (ii) 25,000,000 shares of “blank check” Preferred Stock.

On August 15, 2012, our board of directors and stockholders owning a majority of our outstanding common shares, authorized a 50 for 1 forward stock split of our issued and outstanding common stock. The forward split became effective on September 27, 2012. Due to the forward split, each outstanding share was split into 50 shares. On March 11, 2014, our board of directors authorized a 1.5 for 1 forward stock split of our common stock in the form of a dividend. In connection therewith, our shareholders of record as of the close of business on March 28, 2014, received an additional 0.5 share of our common stock for each share of our issued and outstanding common stock held by them on such date. The forward stock split became effective on April 1, 2014.

Results of Operations

Comparison of the Three Months Ended June 30, 2022 to the Three Months Ended June 30, 2021

Results of Operations

Comparison of the Three Months Ended December 31, 2022 to the Three Months Ended December 31, 2021

Revenue

No revenue or cost of sales were generated for the three months ended ~~June~~December 3031, 2022 and 2021.

Operating Expenses

The Company’s expenses for the three months ended ~~June~~December 3031, 2022 and 2021, are summarized as follows:

	Three Months Ended June 30,
	Three Months Ended December 31,
	2022		2021
General and administrative (including $6,919 and $15,705 of fees paid to related party)	$	12,091	$	16,845
General and administrative (including $46,012 and $4,770 of fees paid to related party)	$	110,412	$	52,063
Total operating expenses	$	12110,~~091~~412	$	1652,~~845~~063

The ~~decrease~~increase in general and administrative expenses for the three months ended ~~June~~December 3031, 2022 compared to the three months ended ~~June~~ 30December 31, 2021 of $458,~~754~~349 is due primarily to an increase in ~~filing~~accounting fees.

Other Expenses

	Three Months Ended June 30,
	Three Months Ended December 31,
	2022			2021
Interest Expense (including related party interest of $873 and $3)	$	7,951		$	2,361
Interest Expense (including related party interest of $882 and $132)	$	1,830		$	8,831
Gain on forgiveness of debt		~~(28,875~~-	)		-(1,539	)
Total other expenses	$	~~(20~~1,~~924~~830	)	$	27,~~361~~292

Interest expense ~~increased~~decreased $57,~~590~~ 001 for the three months ended ~~June~~December 3031, 2022 from the comparative period of 2021 primarily from accrued ~~interest~~ interest on the Company’s notes payable which decreased as a result of principal payments of $35,000 in June 2022. The gain on forgiveness of debt of $281,~~875~~539 for the ~~nine~~three months ended ~~June~~December 3031, ~~2022~~2021 was a result of a decrease of accounts payable as a result of vendor adjustments.

Comparison of the Nine months Ended June 30, 2022 to the Nine months Ended June 30, 2021

Revenue

No revenue or cost of sales were generated for the nine months ended June 30, 2022 or June 30, 2021.

Operating Expenses

The Company’s expenses for the nine months ended June 30, 2022 and 2021, are summarized as follows:

	Nine Months Ended June 30,
	2022		2021
General and administrative (including $14,968 and $43,283 of fees paid to related party)	$	110,715	$	65,060
Total operating expenses	$	110,715	$	65,060

The increase in general and administrative expenses for the nine months ended June 30, 2022 compared to the nine months ended June 30, 2021 of $45,655 is due primarily to an increase in accounting and audit fees.

Other Expenses

	Nine Months Ended June 30,
	2022			2021
Interest Expense (including related party interest of $1,868 and $3)	$	24,784		$	7,241
Gain on forgiveness of debt		(30,414	)		(3,029	)
Total other expenses	$	(5,630	)	$	4,212

Interest expense increased for the nine months ended June 30, 2022 from the comparative period of 2021 of $17,543 is due primarily to the increase in interest rate to 15% on the Company’s notes payable due to the default rate provisions. The gain on forgiveness of debt of $30,414 and $3,029 for the nine months ended June 30, 2022 and 2021, respectively, was a result of the reduction of accounts payable as a result of vendor adjustments. The increase of $27,385 was a result of the timing differences of the related vendor adjustments.

Liquidity and Capital Resources

Working Capital

The following table sets forth a summary of changes in working capital as of ended ~~June~~December 3031, 2022 and September 30, ~~2021~~2022:

	As of
	June 30, 2022			September 30, 2021
	December 31, 2022			September 30, 2022
Current Assets	$	~~134~~102,~~090~~480		$	~~261~~130,~~152~~349
Current Liabilities		~~565~~705,~~360~~876			~~587~~621,~~337~~503
Working capital	$	(~~431~~603,~~270~~396	)	$	(~~326~~491,~~185~~154	)

The decrease in current assets of $~~127~~27,~~062~~869 is mainly due to a decrease in cash from the payment of outstanding vendor bills ~~and payment of a notes payable of $65,000~~ during the ~~nine~~ three months ended ~~June~~December 3031, 2022. The ~~decrease~~increase in current liabilities of $2184,~~977~~373 is primarily due to aan ~~decrease~~ increase in accounts payable ~~and payments on notes payable~~ during the ~~nine~~three months ended ~~June~~December 3031, 2022, for additional professional fees.

Cash Flows

The following table sets forth a summary of changes in cash flows for the ~~nine~~three months ended ~~June~~December 3031, 2022 and 2021:

	Nine Months Ended June 30,
	Three Months Ended December 31,
	2022			2021
Net cash used in operating activities	$	(6430,~~812~~879	)	$	(~~120~~43,598	)
Net cash used in financing activities		~~(65,000~~-	)		42(30,~~500~~000	)
Change in cash	$	(~~129~~30,~~812~~879	)	$	42(73,~~380~~598	)

As of ~~June~~December 3031, 2022, our cash balance was $~~131~~96,~~340~~720. The Company does not expect its current cash and operating income to be sufficient to to meet its financial needs for continuing operations over the next twelve months.

Net cash used in operations for the ~~nine~~three months ended ~~June~~December 3031, 2022 and 2021 of $6430,~~812~~879 and $43,598, respectively, was mainly due to the net ~~loss~~losses ~~that was~~ incurred during the period.

Net cash used in financing activities for the ~~nine~~three months ended ~~June~~December 3031, ~~2022~~2021 of $6530,000 was due to payment on notes payable during the period.

We may need to evaluate raising additional capital through the sale of equity securities, through an offering of debt securities or through borrowing from individuals. There can be no assurance that such a plan will be successful.

Cash Requirements

As of the date of this filing, we do not have sufficient cash on hand to cover our operating expenses through the next fiscal year. As of December 1631, 2022, we had cash and cash equivalents of approximately $97,000. Our liquidity needs have been satisfied primarily ~~from~~ from the issuance of notes payable. The notes payable are unsecured, matured on September 30, 2021, have not been extended, and are currently in default. There can be no assurance, however, that additional financing will be available or, if it is available, that we will be able to structure such financing on terms acceptable to us and that it will be sufficient to fund our cash requirements until we can reach a level of profitable operations and positive cash flows. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses or experience unexpected cash requirements that would force us to seek additional financing. If additional financing is not available or is not available on acceptable terms, we will have to curtail our operations.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Effects of Inflation

We do not believe that inflation has had a material impact on our business, revenues or operating results during the periods presented.

Critical Accounting Policies and Estimates

Our unaudited condensed financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis. The preparation of unaudited condensed financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of revenues and expenses during the reporting periods.

We regularly evaluate the accounting policies and estimates that we use to prepare our unaudited condensed financial statements. A complete summary of these policies is included in the notes to our unaudited condensed financial statements, along with the related notes contained in our Annual Report on Form 10-K as filed with the Securities & Exchange Commission. In general, management’s estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.

New accounting standards

For discussion of Recently Issued Accounting Pronouncements, see Note 1 to the unaudited condensed financial statements, “Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies” in Part I, Item 1, of this Quarterly Report on Form 10-Q.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Securities Exchange Act of 1934, as amended, or 1934 Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer as appropriate, to allow timely decisions regarding required disclosure. At the end of the quarter ended ~~June~~December 3031, 2022, we carried out an evaluation, under the supervision and with ~~the~~ the participation of our management, including our principal executive officer and the principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures.

We do not have an audit committee: While we are not currently obligated to have an audit committee, including a member who is an “audit committee financial expert,” as defined in Item 407 of Regulation S-K, under applicable regulations or listing standards; however, it is management’s view that such a committee is an important internal control over financial reporting, the lack of which may result in ineffective oversight in the establishment and monitoring of internal controls and procedures.

Based on this evaluation, we determined that as of ~~June~~December 3031, 2022, our disclosure controls and procedures were not effective due to the following:

●	We do not have a majority of independent directors on our board of directors, which may result in ineffective oversight in the establishment and monitoring of required internal controls and procedures.

●	We have an inadequate number of personnel to properly implement control procedures.

●	Due to the size and lack of resources of our Company, we have not fully developed formal accounting policies and procedures.

●	We have not properly complied with all aspects of the Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013.

Management’s Report on Internal Control over Financial Reporting

As of December 31, 2022, management assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and SEC guidance on conducting such assessments. Based on that evaluation, they concluded that during the period covered by this report, such internal controls and procedures were not effective to detect the inappropriate application of US GAAP rules as more fully described below. This was due to deficiencies that existed in the design or operation of our internal controls over financial reporting that adversely affected our internal controls and that may be considered to be material weaknesses.

The matters involving internal controls and procedures that our management considered to be material weaknesses were:

(i)

lack of a functioning audit committee;

(ii)

inadequate segregation of duties consistent with control objectives; and

(iii)

ineffective controls over period-end financial disclosure and reporting processes.

The aforementioned material weaknesses were identified by our Chief Executive and Financial Officer in connection with the review of our financial statements as of December 31, 2022.

Management believes the weaknesses identified above have not had any material effect on our financial statements. However, we are currently reviewing our disclosure controls and procedures related to these material weaknesses and expect to implement changes as soon as practicable and as resources allow, including identifying specific areas within our governance, accounting and financial reporting processes to add adequate resources to remediate these material weaknesses.

Limitations on Effectiveness of Controls and Procedures

Our management, including our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the ~~nine~~three months ended ~~June~~December 3031, 2022 that have materially ~~affected~~ affected or are reasonably likely to materially affect our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company knows of no material pending legal proceedings to which the Company or its Subsidiaries are a party or of which any of its properties, or the properties of its Subsidiaries, are the subject. In addition, the Company does not know of any such proceedings contemplated by any governmental authorities.

The Company knows of no material proceedings in which any of the Company’s directors, officers or affiliates, or any registered or beneficial stockholder is a party adverse to the Company or its Subsidiaries or has a material interest adverse to the Company or its Subsidiaries.

ITEM 1A. RISK FACTORS

An investment in the Company’s common stock involves a number of very significant risks. You should carefully consider the risk factors included in the “Risk Factors” section of the Annual Report on Form 10-K for the year ended September 30, ~~2021~~2022 that was filed on December 19, 2022, in addition to other information contained in those reports and in this quarterly report in evaluating the Company and its business before purchasing shares of its common stock. The Company’s business, operating results and financial condition could be adversely affected due to any of those risks.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5. OTHER INFORMATION

None.

Item 6. Exhibits

Exhibit
Number	Description
(2)	Plan of acquisition, reorganization, arrangement, liquidation or succession
2.1	Articles of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on September 5, 2013)
2.2	Agreement and Plan of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on September 5, 2013)
2.1	Articles of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on March 20, 2014)
2.2	Agreement and Plan of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on March 20, 2014)
2.1	Articles of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on December 30, 2014)
2.2	Agreement and Plan of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on December 30, 2014)
(3)	(i) Articles of Incorporation; and (ii) Bylaws
3.1	Articles of Incorporation (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)
3.1.2	Certificate of Amendment to Articles of Incorporation (incorporated by reference to our Registration Statement on Form 10-K filed on December 26, 2012)
3.1.3	Certificate of Change (incorporated by reference to our Registration Statement on Form 10-K filed on December 26, 2012)
3.2	Bylaws (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)
(4)	Instruments Defining the Rights of Security Holders, Including Indentures
4.1	Specimen Common Stock Certificate (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)
4.1	Form of Registrant’s 10% Senior Convertible Promissory Note (incorporated by reference to our Registration Statement on Form 8-K filed on October 17, 2013)
(10)	Material Contracts
10.1	Convertible Promissory Note dated March 21, 2017 with Trius Holdings Limited (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on March 31, 2016.)
10.2	Convertible Promissory Note dated March 30, 2017 with Sukh Athwal (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on March 31, 2016.)
10.3	Convertible Promissory Note dated January 10, 2018 with Mediapark Investments Limited (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
10.4	Convertible Promissory Note dated April 2, 2018 with Sukh Athwal (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
10.5	First Amendment to Convertible Promissory Note dated May 7, 2018 with Sukh Athwal (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
10.6	First Amendment to Convertible Promissory Note dated May 7, 2018 with Trius Holdings Limited (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
10.7	Promissory Note dated June 14, 2021 with Neil Reithinger (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on December 19, 2022)
10.8	Promissory Note dated June 16, 2021 with Scott Lauer (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on December 19, 2022)
10.9	Promissory Note dated June 30, 2021 with Utopia Capital, LLC (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on December 19, 2022)
10.10	Promissory Note dated July 6, 2021 with Church & Keeler, Inc. (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.11	Promissory Note dated July 6, 2021 with Draper, Inc. (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.12	Promissory Note dated July 6, 2021 with Happy David Walters (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.13	Promissory Note dated July 9, 2021 with Carriage House Capital, Inc. (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.14	Promissory Note dated July 22, 2021 with John Walters Nick, Jr. (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.15	Promissory Note dated July 22, 2021 with Gary Goodman (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.16	Promissory Note dated July 26, 2021 with Stefan Galluppi (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.17	Promissory Note dated August 4, 2021 with Justin Schreiber (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.18	Promissory Note dated August 6, 2021 with Alexander Lim (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.19	Promissory Note dated August 12, 2021 with Aliunde Limited (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.20	Promissory Note dated September 28, 2021 with Neil Reithinger (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
(31)	Rule 13a-14(a)/15d-14(a) Certification
31.1*	Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
31.2*	Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer
(32)	Section 1350 Certification
32.1*	Section 906 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
32.2*	Section 906 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer
(101)*	Interactive Data Files
101.INS	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document)
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

*	Filed herewith.

**	Furnished herewith. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of any registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, and otherwise are not subject to liability under those sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PEAK PHARMACEUTICALS, INC.

By:	/s/ Neil Reithinger
Neil Reithinger
Chief Executive Officer and Chief Financial Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
Date: December 19, 2022
Date: February 9, 2023

Filing Compare · Retrieve Medical Holdings, Inc.